Caroline I. Davis

Caroline I. Davis

Auto-generated profile, based on publicly available information

Caroline I. Davis

Biochemistry and Molecular Biophysics Graduate Group, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, 19104, USA

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 November 2020 in Metallomics
Verified
Journal Article
Open access
PDF file
CDCaroline I Davis
Caroline I Davis
XGXingxing Gu
Xingxing Gu
RKRyan M Kiefer
Ryan M Kiefer
MRMartina Ralle
Martina Ralle
TGTerence P Gade
Terence P Gade
DBDonita C Brady
Donita C Brady
Hepatocellular carcinoma (HCC), the most common primary liver cancer, of which ∼800 000 new cases will be diagnosed worldwide this year, portends a five-year survival rate of merely 17% in patients with unresectable disease. This dismal prognosis is due, at least in part, from the late stage of diagnosis and the limited efficacy of systemic therapies. As a result, there is an urgent need to identify risk factors that contribute to HCC initiation and provide targetable vulnerabilities to improve patient survival. While myriad risk factors are known, elevated copper (Cu) levels in HCC patients and the incidence of hepatobiliary malignancies in Wilson disease patients, which exhibit hereditary liver Cu overload, suggests the possibility that metal accumulation promotes malignant transformation. Here we found that expression of the Cu transporter genes ATP7A, ATP7B, SLC31A1, and SLC31A2 was significantly altered in liver cancer samples and were associated with elevated Cu levels in liver cancer tissue and cells. Further analysis of genomic copy number data revealed that alterations in Cu transporter gene loci correlate with poorer survival in HCC patients. Genetic loss of the Cu importer SLC31A1 (CTR1) or pharmacologic suppression of Cu decreased the viability, clonogenic survival, and anchorage-independent growth of human HCC cell lines. Mechanistically, CTR1 knockdown or Cu chelation decreased glycolytic gene expression and downstream metabolite utilization and as a result forestalled tumor cell survival after exposure to hypoxia, which mimics oxygen deprivation elicited by transarterial embolization, a standard-of-care therapy used for patients with unresectable HCC. Taken together, these findings established an association between altered Cu homeostasis and HCC and suggest that limiting Cu bioavailability may provide a new treatment strategy for HCC by restricting the metabolic reprogramming necessary for cancer cell survival.

1 May 2019 in Cancer Research
Verified
Journal Article
Closed access
PDF file
BKBryson W Katona
Bryson W Katona
RGRebecca A. Glynn
Rebecca A. Glynn
KPKayla E. Paulosky
Kayla E. Paulosky
ZFZijie Feng
Zijie Feng
CDCaroline I. Davis
Caroline I. Davis
XHXianxin Hua
Xianxin Hua
Menin is a nuclear epigenetic regulator that can both promote and suppress tumor growth in a highly tissue-specific manner. The role of menin in colorectal cancer, however, remains unclear. Here, we demonstrate that menin was overexpressed in colorectal cancer and that inhibition of menin synergized with small-molecule inhibitors of EGFR (iEGFR) to suppress colorectal cancer cells and tumor xenografts in vivo in an EGFR-independent manner. Mechanistically, menin bound the promoter of SKP2, a pro-oncogenic gene crucial for colorectal cancer growth, and promoted its expression. Moreover, the iEGFR gefitinib activated endoplasmic reticulum calcium channel inositol trisphosphate receptor 3 (IP3R3)–mediated release of calcium, which directly bound menin. Combined inhibition of menin and iEGFR-induced calcium release synergistically suppressed menin-mediated expression of SKP2 and growth of colorectal cancer. Together, these findings uncover a molecular convergence of menin and the iEGFR-induced, IP3R3-mediated calcium release on SKP2 transcription and reveal opportunities to enhance iEGFR efficacy to improve treatments for colorectal cancer. Significance: Menin acts as a calcium-responsive regulator of SKP2 expression, and small molecule EGFR inhibitors, which induce calcium release, synergize with Menin inhibition to reduce SKP2 expression and suppress colorectal cancer.

31 March 2023
Verified
Other
Open access
BKBryson W. Katona
Bryson W. Katona
RGRebecca A. Glynn
Rebecca A. Glynn
KPKayla E. Paulosky
Kayla E. Paulosky
ZFZijie Feng
Zijie Feng
CDCaroline I. Davis
Caroline I. Davis
XHXianxin Hua
Xianxin Hua
Supplemental Figure S1: Menin inhibition has minimal effects on cell growth in colon cancer cells. Supplemental Figure S2: Inhibition of menin selectively sensitizes colon cancer cells to iEGFRs. Supplemental Figure S3: BAPTA rescues cells from the combination of gefitinib plus MI-2-2. Supplemental Figure S4: SERCA2 over-expression rescues cells from thapsigargin but not gefitinib. Supplemental Figure S5: Gefitinib induced CRC suppression is mediated by activation of IP3R3. Supplemental Figure S6: Menin inhibition, gefitinib, and TG all decrease SKP2 levels. Supplemental Figure S7: Regulation of SKP2 transcription by menin and intracellular calcium levels.

31 March 2023
Verified
Other
Open access
BKBryson W. Katona
Bryson W. Katona
RGRebecca A. Glynn
Rebecca A. Glynn
KPKayla E. Paulosky
Kayla E. Paulosky
ZFZijie Feng
Zijie Feng
CDCaroline I. Davis
Caroline I. Davis
XHXianxin Hua
Xianxin Hua
Menin is a nuclear epigenetic regulator that can both promote and suppress tumor growth in a highly tissue-specific manner. The role of menin in colorectal cancer, however, remains unclear. Here, we demonstrate that menin was overexpressed in colorectal cancer and that inhibition of menin synergized with small-molecule inhibitors of EGFR (iEGFR) to suppress colorectal cancer cells and tumor xenografts in vivo in an EGFR-independent manner. Mechanistically, menin bound the promoter of SKP2, a pro-oncogenic gene crucial for colorectal cancer growth, and promoted its expression. Moreover, the iEGFR gefitinib activated endoplasmic reticulum calcium channel inositol trisphosphate receptor 3 (IP3R3)–mediated release of calcium, which directly bound menin. Combined inhibition of menin and iEGFR-induced calcium release synergistically suppressed menin-mediated expression of SKP2 and growth of colorectal cancer. Together, these findings uncover a molecular convergence of menin and the iEGFR-induced, IP3R3-mediated calcium release on SKP2 transcription and reveal opportunities to enhance iEGFR efficacy to improve treatments for colorectal cancer.Significance:Menin acts as a calcium-responsive regulator of SKP2 expression, and small molecule EGFR inhibitors, which induce calcium release, synergize with Menin inhibition to reduce SKP2 expression and suppress colorectal cancer.

31 March 2023
Verified
Other
Open access
BKBryson W. Katona
Bryson W. Katona
RGRebecca A. Glynn
Rebecca A. Glynn
KPKayla E. Paulosky
Kayla E. Paulosky
ZFZijie Feng
Zijie Feng
CDCaroline I. Davis
Caroline I. Davis
XHXianxin Hua
Xianxin Hua
Supplemental Figure S1: Menin inhibition has minimal effects on cell growth in colon cancer cells. Supplemental Figure S2: Inhibition of menin selectively sensitizes colon cancer cells to iEGFRs. Supplemental Figure S3: BAPTA rescues cells from the combination of gefitinib plus MI-2-2. Supplemental Figure S4: SERCA2 over-expression rescues cells from thapsigargin but not gefitinib. Supplemental Figure S5: Gefitinib induced CRC suppression is mediated by activation of IP3R3. Supplemental Figure S6: Menin inhibition, gefitinib, and TG all decrease SKP2 levels. Supplemental Figure S7: Regulation of SKP2 transcription by menin and intracellular calcium levels.

31 March 2023
Verified
Other
Open access
BKBryson W. Katona
Bryson W. Katona
RGRebecca A. Glynn
Rebecca A. Glynn
KPKayla E. Paulosky
Kayla E. Paulosky
ZFZijie Feng
Zijie Feng
CDCaroline I. Davis
Caroline I. Davis
XHXianxin Hua
Xianxin Hua
Menin is a nuclear epigenetic regulator that can both promote and suppress tumor growth in a highly tissue-specific manner. The role of menin in colorectal cancer, however, remains unclear. Here, we demonstrate that menin was overexpressed in colorectal cancer and that inhibition of menin synergized with small-molecule inhibitors of EGFR (iEGFR) to suppress colorectal cancer cells and tumor xenografts in vivo in an EGFR-independent manner. Mechanistically, menin bound the promoter of SKP2, a pro-oncogenic gene crucial for colorectal cancer growth, and promoted its expression. Moreover, the iEGFR gefitinib activated endoplasmic reticulum calcium channel inositol trisphosphate receptor 3 (IP3R3)–mediated release of calcium, which directly bound menin. Combined inhibition of menin and iEGFR-induced calcium release synergistically suppressed menin-mediated expression of SKP2 and growth of colorectal cancer. Together, these findings uncover a molecular convergence of menin and the iEGFR-induced, IP3R3-mediated calcium release on SKP2 transcription and reveal opportunities to enhance iEGFR efficacy to improve treatments for colorectal cancer.Significance:Menin acts as a calcium-responsive regulator of SKP2 expression, and small molecule EGFR inhibitors, which induce calcium release, synergize with Menin inhibition to reduce SKP2 expression and suppress colorectal cancer.